Longevity Funding Tracker (125 deals)

Our funding tracker covering the longevity market

Below is the table listing all the deals. You may find our methodology at the end of this page.

And, if you want to gain a deeper understanding of the market and its current dynamics, get our longevity market report.

Is longevity really a $4 billion funding market right now?

Longevity funding currently adds up to $4.10 billion in our research, but most companies are operating in a much smaller funding market than that headline suggests.

We tracked 119 distinct financing events across 96 companies from January 1, 2024 through the end of our research window. Among the 111 rounds where we could establish a usable amount, the median financing was $10 million while the average reached $36.9 million.

A few giant rounds create most of that gap. Once we remove financings above $50 million, measured capital falls to $1.17 billion. Ten rounds of $100 million or more account for almost 60% of all the money we measured.

The monthly pattern makes the same point. A normal completed month had three deals and $55.1 million of known capital. January 2026 jumped to 11 deals, while July 2026 reached $745.5 million with only six. Longevity funding is active fairly regularly, but the dollar totals can change completely when one large company comes back to market.

The latest partial month in our window already contains another qualifying financing, so activity has not simply stopped. For now, the cleaner way to read the market is to separate ordinary venture funding from the much rarer scale-up rounds that dominate the total.

How many funded longevity companies are there actually?

Funded longevity is currently a sub-100-company market: we found 96 companies across nearly 33 months of financing activity.

Seventy-six of those companies appear only once in the funding window. Seventeen raised twice, while only three show up three times or more.

That makes the market smaller than the raw deal count initially suggests. There are plenty of longevity experiments being financed, but the group that repeatedly gets institutional capital is narrow. Only 20 companies completed more than one qualifying financing during the period.

Those repeat fundraisers are especially important because they absorb a majority of the money. A lot of companies manage to enter the market once; far fewer build a financing history.

Is longevity funding concentrated in just a handful of companies?

Longevity funding is heavily concentrated today, with the five largest companies taking 55.8% of all measured capital.

Neko Health sits far ahead of the rest with almost $1 billion raised during the window. NewLimit follows at $610 million and Function Health at $351 million. By the time we reach the tenth-largest company, this small group has absorbed 69.2% of the market's money.

The bottom of the distribution looks completely different. Around 30% of companies never get beyond $5 million of cumulative capital during the window, while only 15.6% cross $50 million.

Company-level concentration is especially useful here because the same winners keep raising again. Looking only at the largest individual deals would understate how much capital repeatedly flows back toward a small group.

Company	Capital raised in window	Qualifying rounds
Neko Health	$987.5M	3
NewLimit	$610M	3
Function Health	$351M	2
BioAge Labs	$170M	1
Loyal	$167M	3
Corsera Health	$130M	2
Prenuvo	$120M	1
Lanserhof Group	$110.3M	1
Cognito Therapeutics	$105M	1
Tenpoint Therapeutics	$85M	1

Is Neko Health distorting the longevity funding market?

Neko Health currently has enough financial weight to distort the apparent size of preventive health, Sweden and individual funding months all at once.

Across three financings, Neko raised about $987.5 million, equal to 24.1% of all measured capital. Its $700 million Series C alone accounts for 17.1%. Neko alone holds nearly a quarter of the measured money, so we look at who the top companies are today in our longevity market report.

The company also explains much of the apparent capital intensity in preventive health. Neko contributes 41.8% of all funding in that category. Sweden similarly looks enormous in country-level statistics largely because Neko happens to be Swedish.

There is a real operating story underneath the funding, though. At the time of its 2026 financing, Neko said more than 100,000 people had already used its preventive scans in Sweden and the UK, with more than 350,000 people registered or waiting. The company was using the new capital for U.S. expansion, additional clinics and further development of its own diagnostic infrastructure.

So Neko is both a genuine scale company and a major statistical outlier. Taking it out would make several market-level charts look very different.

What does a normal longevity startup raise these days?

A normal longevity startup currently raises around $10 million; the $36.9 million average round is pulled upward by a small number of exceptional financings.

Two-thirds of the rounds where we could establish a size were below $20 million. We counted 29 financings below $5 million and another 45 between $5 million and $20 million.

Those 74 deals together produced only about 12% of measured capital. At the other end, fewer than one financing in ten reached $100 million, yet those rounds captured close to three-fifths of the money.

For founders, the practical benchmark is much closer to a high-single-digit or low-eight-figure round than to the market average. The giant checks belong to companies that have already crossed a very different threshold of clinical, commercial or infrastructure scale.

Which parts of longevity are investors actually funding?

Serious longevity money currently sits overwhelmingly in therapeutic developers and preventive-health platforms.

Therapeutics attracted $1.79 billion across 48 financings. Preventive-health platforms received another $1.67 billion across 34. Together, those two categories captured roughly 84% of all measured capital.

The rest of the market is much smaller. Healthy-aging clinics raised $242.1 million, consumer longevity brands $229.7 million, aging-research platforms $103 million and diagnostics or biomarker companies $63.4 million.

What stands out is that therapeutics and preventive health reach similar capital totals in very different ways. Therapeutics have the broader company base and a larger median round. Preventive health contains fewer companies but several exceptionally capital-hungry businesses such as Neko Health, Function Health and Prenuvo.

Category	Deals	Companies	Capital	Median round
Longevity Therapeutics Developers	48	39	$1.79B	$11.7M
Preventive Health Platforms	34	25	$1.67B	$7.0M
Healthy Aging Clinics	12	10	$242.1M	$8.7M
Consumer Longevity Brands	10	8	$229.7M	$17.5M
Aging Research Platforms	8	8	$103.0M	$8.5M
Diagnostics/Biomarker Companies	7	6	$63.4M	$5.0M

Why are preventive-health longevity companies raising such huge rounds?

Preventive-health longevity rounds get huge when the business combines software with expensive real-world healthcare delivery.

Neko Health is the clearest example. Its model combines proprietary scanning hardware, software, clinicians and physical clinics. International expansion means opening locations, building diagnostic capacity and operating a healthcare service rather than simply acquiring app users. Scanners, software and physical clinics under one roof make a heavy model, and in our report on longevity we compare which business models are winning.

Function Health has followed another capital-heavy route. Its $298 million Series B came after the company had expanded beyond recurring laboratory testing into imaging through its acquisition of Ezra, while also building longitudinal health data and AI-supported medical intelligence.

Prenuvo adds a third version of the same model. The company disclosed a $120 million Series B after building its preventive-health offering around whole-body MRI and related diagnostic products.

These businesses help explain why preventive health can look unusually well funded even with a modest $7 million median round. The biggest companies in the category are financing technology, medical operations, physical capacity, data systems and expansion at the same time.

Why can longevity therapeutics raise hundreds of millions?

Longevity therapeutics can raise hundreds of millions because the expensive phase begins when promising aging science turns into a real clinical-development program.

NewLimit shows that transition clearly. The company raised $435 million in Series C financing to move its epigenetic-reprogramming work toward human trials after previously raising $130 million in Series B funding.

BioAge raised $170 million to advance clinical programs based on human aging biology. Its more recent financial reporting still showed quarterly R&D spending running into the tens of millions of dollars as those programs moved forward.

Cognito Therapeutics raised $105 million in Series C funding around its Alzheimer's treatment platform, while Loyal raised $100 million to push its lead canine-longevity drug through late development and toward commercial readiness.

By that stage, investors are financing clinical trials, manufacturing, regulatory work, scientific teams and years of runway. The jump from research company to therapeutic developer naturally creates much larger capital requirements.

Is longevity funding still mostly early-stage today?

Most longevity rounds are still early-stage today, but most of the money goes to the few companies that make it further.

Seed alone represents half of all financing events in our research. Adding Series A brings early-stage activity to 78.6% of classified deals.

The capital distribution points in the opposite direction. Seed and Series A receive only 24% of classified funding, while Series B and beyond absorb the majority.

Check sizes climb quickly as companies move up the ladder. The median rises from $5.3 million at Seed to $20 million at Series A and $60.5 million at Series B. Series C is where the scale changes dramatically.

Stage	Deals	Share of deals	Capital	Median round
Seed	60	50.4%	$372.8M	$5.3M
Series A	21	17.6%	$567.0M	$20.0M
Series B	12	10.1%	$1.14B	$60.5M
Series C	4	3.4%	$1.34B	$270M
Series D+	5	4.2%	$377.5M	$66M
Growth Equity	1	0.8%	$110.3M	$110.3M
Unknown	16	13.4%	$187.4M	$6.0M

Why do so few longevity companies make it to Series C?

The longevity funding ladder narrows hard before Series C, exactly where the required checks become much larger.

We counted 60 Seed financings, 21 Series A rounds, 12 Series B rounds and only four Series C financings. These are not cohort-conversion rates, since the companies did not all start at the same time, but the shape of the visible market is still unusually clear.

Companies are also much older by the time they reach that level. Median age moves from two years at Seed to 5.5 years at Series A, six at Series B and 7.5 at Series C. Companies raising more than $50 million have a median age of seven years, compared with two years for companies raising below $5 million.

The few businesses that reach Series C then enter a much richer funding environment. The median Series C in our research is $270 million. That is a pretty small club.

NewLimit illustrates the therapeutic path, while Neko shows the preventive-health version. Both spent years building before receiving their largest checks. In practice, Series C marks entry into a much rarer group of companies that investors are willing to finance at genuine scale.

Are investors backing new longevity startups or mostly doubling down?

Longevity investors currently put most of their money into companies that have already raised before.

We classified 34 financings as first financings and 82 as follow-ons. First financings had a $6 million median round; follow-ons reached $12.6 million.

The difference becomes much larger in dollars. Follow-ons account for roughly 88% of measurable capital. Follow-ons now take most of the money, so we break down who is getting funded, and by whom, in our longevity market report.

As seen above, only 20 companies raised more than once during the window, yet those repeat fundraisers captured about 61% of the money. Neko, NewLimit, Function Health and Loyal all show how quickly capital can compound once a company becomes part of that group.

Even the latest qualifying financing in our window, Aeon's Seed extension, was a follow-on rather than a brand-new company entering the market. Longevity still creates new startups, but the biggest pool of capital these days is supporting businesses that already have financing history.

Do pharma and other strategic investors actually care about longevity?

Strategic investors care about longevity mainly when the company looks relevant to drug development or another established industrial business.

We found at least one strategic investor in 17 of the 119 financings, or 14.3%. The median strategic-backed round was $24.25 million versus $8.7 million for rounds without a strategic investor.

Therapeutics dominate this activity, accounting for 11 of those 17 deals. Eli Lilly appears around longevity drug development, Boehringer Ingelheim Venture Fund backed both Refoxy and TECregen, and Merck Animal Health participated alongside a research collaboration with Rejuvenate Bio.

Preventive platforms and consumer brands attract occasional strategic money, while the 12 clinic financings in our research contain none.

Strategic capital adds real weight to one part of longevity rather than the whole market. Pharma and other industrial groups are showing the clearest interest where aging science can feed directly into regulated products, therapeutic programs or proprietary technology.

Which investors keep leading longevity funding rounds?

Longevity funding leadership is still fragmented: we identified 99 named lead or co-lead investors, and only eight appear more than once.

Lightspeed Venture Partners is the most financially visible repeat lead because of its involvement in two large Neko rounds. Forerunner Ventures, Left Lane Capital and Khosla Ventures also recur, along with a handful of smaller repeat names.

Even then, financings touched by one of these recurring leads represent only about 15% of deals where we could identify a lead investor.

There is currently no small group underwriting most longevity financings from Seed through growth. Founders are raising from a changing mix of biotech specialists, healthcare investors, generalist venture firms, growth funds and strategic investors depending on what the company actually does.

Repeat lead/co-lead	Deals	Combined size of rounds concerned
Lightspeed Venture Partners	2	$960M
Forerunner Ventures	2	$147.9M
Left Lane Capital	2	$130M
Khosla Ventures	2	$52M
Boehringer Ingelheim Venture Fund	2	$22.2M
Goldcrest Capital	2	$20M
Godfrey Capital	2	$20M
RTP Global	2	$16M

Where is longevity funding actually happening?

Longevity funding currently lives overwhelmingly in North America and Europe.

North America generated 66 financings across 53 companies and $2.46 billion of measured capital. Europe added 34 deals across 28 companies and $1.53 billion.

Together, those two regions account for roughly 97% of the money in our research.

Asia-Pacific is active at the smaller end, with 15 financings, but the region raised only $94.5 million and produced no round above $50 million during the window. The Middle East contributed four deals and $11.4 million.

The United States alone represents about 59.8% of measured capital. Europe is smaller by deal count but attracts more money per deal than its share of activity would suggest.

For now, the major scale rounds remain overwhelmingly American or European.

What is the longevity funding market still missing?

The biggest thing longevity funding still lacks is a broad middle-to-late-stage population outside therapeutics and preventive health.

Aging Research Platforms have eight deals in our research, but none carries a classified Series A, B or C label. Diagnostics and biomarker companies reach Series A but go no further in the visible financing ladder. Diagnostics companies that stop at Series A leave a visible gap; we look at where the biggest opportunities are in our longevity market report.

Healthy-aging clinics have real deal activity, yet one mature Lanserhof transaction accounts for almost half of the category's capital. Clinics also have no identified strategic-backed financing.

Those absences should be read with some care. Stage could not be reliably established for 13.4% of financings, lead-investor information is missing for 27.7%, and eight qualifying rounds have no exact disclosed amount. Extensions, additional closes, secondary components and conflicting source reports also make individual transactions less comparable than a clean spreadsheet might imply.

Even allowing for those gaps, the pattern is hard to ignore. The market currently has plenty of company formation and plenty of Seed activity. What remains scarce is the larger population of companies that can repeatedly raise $50 million, $100 million or more.

What should we actually take away from longevity funding today?

Longevity funding today is best understood as a small early-company ecosystem with a highly concentrated scale-capital layer.

The ordinary financing market sits around low eight figures, while a handful of mature companies operate in a completely different financial league. Those outliers make the market look far larger in aggregate than it feels to most founders.

Serious money is clustering around two models: therapeutic development and capital-heavy preventive healthcare. Other parts of longevity are getting funded, but they rarely reach the same scale.

Investors also become much more generous after companies build a financing history. New startups keep appearing, while the deepest pools of capital increasingly flow toward businesses that have already survived several years, raised before and reached a credible clinical or commercial milestone.

The biggest weakness these days is graduation rather than company creation. Longevity produces plenty of Seeds. It produces far fewer businesses capable of sustaining repeated scale rounds.